Business · 14/10/1998Updated: 10/17/2026 · 1 min read
FDA Extends Comment Period for Proposed Rule on In Vivo Radiopharmaceuticals
Summary
The Food and Drug Administration (FDA) is extending the comment period for a proposed rule on in vivo radiopharmaceuticals used for diagnosis and monitoring until November 16, 1998, to provide interested persons with additional time to submit comments on the proposed rule.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →